According to a new report by Rockville Research, the global psoriasis treatment market is estimated to be valued at US$ 27 billion in the year 2025, growing at a CAGR of 8.9% in the period 2019 to 2025. Growth of the market is driven by factors such as rising incidences of the autoimmune diseases, changing lifestyle, ageing population, increasing availability of biologics and biosimilars and growing awareness about the disease.
Psoriasis is a complex, chronic, inflammatory skin disorder that is characterized by itchy skin lesions. It involves hyperproliferation of the keratinocytes which leads to substantial increase in in the epidermal cell turnover rate.
Psoriasis therapeutics market is expected to witness substantial uptake of Biosimilars for currently marketed biologics. The market is expected to get slew of these novel products in the upcoming years. Currently, there are very few biosimilars approved for the treatment of psoriasis and psoriatic arthritis.
This report "Global Psoriasis Treatment Market [By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region - North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025]" provides a detailed analysis of the global psoriasis therapeutics market from qualitative and quantitative outlooks during the forecast period across various therapeutic classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Base year 2016
Forecast period 2019 - 2025
Market sizing Revenue in US$ Billions & CAGR for the period 2019 to 2025
Country coverage The US, The UK, Germany & Japan
Vendor scope AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Eli Lilly & Company, Inc.
Report coverage Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, Rockville Research has segmented global psoriasis therapeutics market report has been segmented on the basis of drug classes and region:-
Therapeutic Class Outlook, Revenue (2017 - 2025E, US$ Billions)
> Tumor necrosis factor-alpha (TNF-alpha) Inhibitors
> Interleukin (IL) Inhibitors
> T-cell Inhibitors
Regional Outlook, Revenue (2017 - 2025E, US$ Billions)
> North America
> Asia Pacific
Country Outlook, Revenue (2017 - 2025E, US$ Billions)
> The US
> The UK
Vendors Outlook, Revenue (2013 - 2022E, US$ Billions)
> AbbVie Inc.
> Amgen Inc.
> Johnson & Johnson
> Novartis AG
> Eli Lilly & Company, Inc.
> Psoriasis Drug Manufacturers
> Chemical Suppliers
> End Users
> Research Professionals
> Healthcare Consultancies
> Regulatory Bodies
Key questions answered in the report
> Historical market size of migraine therapeutics from 2016 to 2018 in US$ Billions.
> Projected market growth in the forecasted period 2019 to 2025 with estimated revenue for each year in US$ Billions.
> Revenue forecasts of major psoriasis therapeutics in the period 2016 to 2025 in US$ Billions.
> Regional and country of migraine therapeutics in the period 2017 to 2025 in US$ Billions.
> Market drivers, restraints and industry trends that has impact on revenue.
> Profiling of major companies with detailed analysis of major psoriasis therapeutics approved for marketing as well as in pipeline.
We provide customization of the study in order to provide specific information as sought by the client.